Director Adam M. Koppel resigns from Foghorn Therapeutics board

Foghorn Therapeutics Inc.

Adam M. Koppel, M.D., Ph.D., resigned from the Board effective December 29, 2024.
Resignation not due to any disagreement with the Company or Board.
Koppel served on the Audit Committee and Nominating and Corporate Governance Committee.
He was a Class II director with a term expiring at the 2025 Annual Meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.